1018 related articles for article (PubMed ID: 25696840)
21. Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with
Miyaoka M; Kikuti YY; Carreras J; Ito A; Ikoma H; Tomita S; Kawada H; Roncador G; Bea S; Campo E; Nakamura N
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497332
[TBL] [Abstract][Full Text] [Related]
22. Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.
Alsuwaidan A; Pirruccello E; Jaso J; Koduru P; Garcia R; Krueger J; Doucet M; Chaudhry R; Fuda F; Chen W
Cytometry B Clin Cytom; 2019 Sep; 96(5):368-374. PubMed ID: 30734478
[TBL] [Abstract][Full Text] [Related]
23. Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology.
Moore EM; Aggarwal N; Surti U; Swerdlow SH
Am J Surg Pathol; 2017 Sep; 41(9):1155-1166. PubMed ID: 28614202
[TBL] [Abstract][Full Text] [Related]
24. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
25. Advances in pathological understanding of high-grade B cell lymphomas.
Li S; Lin P; Medeiros LJ
Expert Rev Hematol; 2018 Aug; 11(8):637-648. PubMed ID: 29989509
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
[TBL] [Abstract][Full Text] [Related]
27. Double-hit and double-expressor primary central nervous system lymphoma: Experience from North India of an infrequent but aggressive variant.
Parkhi M; Chatterjee D; Radotra BD; Bal A; Yadav BS; Tripathi M
Surg Neurol Int; 2023; 14():172. PubMed ID: 37292392
[TBL] [Abstract][Full Text] [Related]
28. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
Kodet R; Mrhalová M; Stejskalová E; Kabícková E
Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
[TBL] [Abstract][Full Text] [Related]
29. [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].
Gerhard-Hartmann E; Rosenwald A
Pathologe; 2020 Nov; 41(6):574-581. PubMed ID: 32909092
[TBL] [Abstract][Full Text] [Related]
30. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
Cinar M; Rosenfelt F; Rokhsar S; Lopategui J; Pillai R; Cervania M; Pao A; Cinar B; Alkan S
Leuk Res; 2015 Jul; 39(7):730-8. PubMed ID: 25916698
[TBL] [Abstract][Full Text] [Related]
31. Aggressive B-cell lymphomas: frequency, immunophenotype, and genetics in a reference laboratory population.
Naeini YB; Wu A; O'Malley DP
Ann Diagn Pathol; 2016 Dec; 25():7-14. PubMed ID: 27806850
[TBL] [Abstract][Full Text] [Related]
32. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
Hematol Oncol; 2010 Jun; 28(2):53-6. PubMed ID: 19844983
[TBL] [Abstract][Full Text] [Related]
33. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.
Li S; Seegmiller AC; Lin P; Wang XJ; Miranda RN; Bhagavathi S; Medeiros LJ
Mod Pathol; 2015 Feb; 28(2):208-17. PubMed ID: 25103070
[TBL] [Abstract][Full Text] [Related]
34. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.
Pham LV; Lu G; Tamayo AT; Chen J; Challagundla P; Jorgensen JL; Medeiros LJ; Ford RJ
J Hematol Oncol; 2015 Oct; 8():121. PubMed ID: 26515759
[TBL] [Abstract][Full Text] [Related]
35. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience.
Pedersen MØ; Gang AO; Poulsen TS; Knudsen H; Lauritzen AF; Nielsen SL; Gang UO; Nørgaard P
Eur J Haematol; 2012 Jul; 89(1):63-71. PubMed ID: 22510149
[TBL] [Abstract][Full Text] [Related]
36. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases.
Perry AM; Crockett D; Dave BJ; Althof P; Winkler L; Smith LM; Aoun P; Chan WC; Fu K; Greiner TC; Bierman P; Gregory Bociek R; Vose JM; Armitage JO; Weisenburger DD
Br J Haematol; 2013 Jul; 162(1):40-9. PubMed ID: 23600716
[TBL] [Abstract][Full Text] [Related]
37. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
Pina-Oviedo S; Bellamy WT; Gokden M
Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
[TBL] [Abstract][Full Text] [Related]
38. Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review.
Xu X; Zhang L; Wang Y; Zhang Q; Zhang L; Sun B; Zhang Y
Int J Clin Exp Pathol; 2013; 6(4):788-94. PubMed ID: 23573328
[TBL] [Abstract][Full Text] [Related]
39. Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.
Bischin AM; Dorer R; Aboulafia DM
Clin Med Insights Blood Disord; 2017; 10():1179545X17692544. PubMed ID: 28579851
[TBL] [Abstract][Full Text] [Related]
40. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
